The Case for Simulating Pregnancy
Pregnant women are routinely excluded from drug trials, leaving clinicians without dosing guidance. Discover how…
CertaraJune 9, 2026
The end of the national launch: why regional pharma market access now determines commercial success
Regional pharma market access is reshaping uptake. Build a regional market access strategy to navigate…
CertaraJune 5, 2026
Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients
See how a QSP model guided efficacy-proximal FIH dosing for ISB 2001 in the TRIgnite-1…
CertaraJune 4, 2026
Applying AI-Driven Biosimulation to Drug Discovery
Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…
CertaraJune 2, 2026
Model-Informed Development Accelerates Transformative Treatment for Sleeping Sickness
Certara’s drug development support enabled a positive scientific opinion from the EMA for acoziborole, a…
CertaraJune 2, 2026
Strategies for navigating loss of exclusivity (LOE) in pharma
Learn key strategies to navigate loss of exclusivity with confidence & defend market share throughout…
CertaraJune 2, 2026
Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment
This review explores how artificial intelligence (AI), machine learning (ML), and quantitative systems pharmacology (QSP)…
CertaraJune 2, 2026
How to Choose the Right LLM for Medical Writing
What makes great GenAI medical writing software? See how medical writing artificial intelligence and model…
CertaraMay 28, 2026
Certara’s NLME Engine: Setting the Standard for Run Speed and Stability
Why pharmacometricians are turning to the NLME engine from Certara Phoenix
CertaraMay 28, 2026
